Free tool
Upcoming earnings calendar
See who reports in the next 30, 60 or 90 days, from the ~22,000 stocks we cover — filter by cap, sector, theme or market, then open any ticker for the full analysis.
See who reports in the next 30, 60 or 90 days, from the ~22,000 stocks we cover — filter by cap, sector, theme or market, then open any ticker for the full analysis.
See who reports in the US in the next 90 days, from the ~22,000 stocks we cover — filter by cap, sector, theme or market, then open any ticker for the full analysis.
33 companies reporting in the next 90 days. Clear filters
Data as of Aug 26, 2026 · updates nightly, Mon–Sat
| Ticker | Company | Theme | Market cap (USD) | 1M return | |
|---|---|---|---|---|---|
| Monday, Oct 26 · in 60 days · 2 companies | |||||
| BMRN | BioMarin Pharmaceutical Inc. | Rare disease | $12.80B | +9.71% | |
| 0HNC.L | BioMarin Pharmaceutical Inc. | Rare disease | $9.93B | +0.37% | |
| Tuesday, Oct 27 · in 61 days · 1 company | |||||
| ARQT | Arcutis Biotherapeutics, Inc. | Rare disease | $3.12B | −10.70% | |
| Wednesday, Oct 28 · in 62 days · 1 company | |||||
| BBIO | BridgeBio Pharma, Inc. | Rare disease | |||
Price chart, technicals, money flow, fundamentals and an AI-written read — one page per stock. Looking for a name that isn't listed? Jump straight to it:
| $15.85B |
| −4.42% |
| Thursday, Oct 29 · in 63 days · 6 companies | |||||
| 0HD2.L | Alnylam Pharmaceuticals, Inc. | Rare disease | $35.05B | −4.67% | |
| ALNY | Alnylam Pharmaceuticals, Inc. | Rare disease | $32.12B | −13.76% | |
| DUL.DE | Alnylam Pharmaceuticals, Inc. | Rare disease | $31.87B | −20.91% | |
| INSM | Insmed Incorporated | Rare disease | $27.07B | +18.29% | |
| 0JAV.L | Insmed Incorporated | Rare disease | $12.89B | +0.69% | |
| TVTX | Travere Therapeutics, Inc. | Rare disease | $6.06B | +18.23% | |
| Monday, Nov 2 · in 67 days · 4 companies | |||||
| VX1.DE | Vertex Pharmaceuticals Incorporated | Rare disease | $140.77B | +10.56% | |
| VRTX | Vertex Pharmaceuticals Incorporated | Rare disease | $140.04B | +15.42% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | Rare disease | $112.52B | +1.12% | |
| BCRX | BioCryst Pharmaceuticals, Inc. | Rare disease | $2.51B | +2.61% | |
| Tuesday, Nov 3 · in 68 days · 5 companies | |||||
| KYMR | Kymera Therapeutics, Inc. | Rare disease | $10.53B | +15.07% | |
| RYTM | Rhythm Pharmaceuticals, Inc. | Rare disease | $7.78B | +6.80% | |
| LQDA | Liquidia Corporation | Rare disease | $6.31B | −16.50% | |
| RARE | Ultragenyx Pharmaceutical Inc. | Rare disease | $2.61B | −1.60% | |
| STOK | Stoke Therapeutics, Inc. | Rare disease | $2.16B | +14.16% | |
| Wednesday, Nov 4 · in 69 days · 2 companies | |||||
| MIRM | Mirum Pharmaceuticals, Inc. | Rare disease | $5.98B | −14.12% | |
| ADMA | ADMA Biologics, Inc. | Rare disease | $2.14B | +14.62% | |
| Thursday, Nov 5 · in 70 days · 6 companies | |||||
| CYTK | Cytokinetics, Incorporated | Rare disease | $10.77B | −3.92% | |
| PTGX | Protagonist Therapeutics, Inc. | Rare disease | $10.01B | +11.09% | |
| EWTX | Edgewise Therapeutics, Inc. | Rare disease | $4.80B | +6.27% | |
| AMLX | Amylyx Pharmaceuticals, Inc. | Rare disease | $4.17B | +92.20% | |
| VRDN | Viridian Therapeutics, Inc. | Rare disease | $2.74B | +22.74% | |
| VERA | Vera Therapeutics, Inc. | Rare disease | $2.54B | +0.28% | |
| Tuesday, Nov 10 · in 75 days · 1 company | |||||
| MLYS | Mineralys Therapeutics, Inc. | Rare disease | $2.32B | −3.20% | |
| Wednesday, Nov 11 · in 76 days · 1 company | |||||
| ORKA | Oruka Therapeutics, Inc. | Rare disease | $6.74B | +12.88% | |
| Thursday, Nov 12 · in 77 days · 3 companies | |||||
| MANE | Veradermics, Incorporated | Rare disease | $4.11B | −8.14% | |
| NKTR | Nektar Therapeutics | Rare disease | $2.52B | +5.06% | |
| ZBIO | Zenas BioPharma, Inc. | Rare disease | $2.20B | +2.89% | |
| Monday, Nov 16 · in 81 days · 1 company | |||||
| COAG | Hemab Therapeutics Holdings, Inc. | Rare disease | $2.32B | −1.47% | |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India). Reporting dates are public estimates and can shift.